Why the study?
Does percutaneous left atrial appendage transcatheter occlusion (PLAATO) safely prevent embolic events in a high-risk AF patient unable to tolerate warfarin?
Does percutaneous left atrial appendage transcatheter occlusion (PLAATO) safely prevent embolic events in a high-risk AF patient unable to tolerate warfarin?
Answers are grounded in this paper and cite their sources.
Percutaneous left atrial appendage transcatheter occlusion (PLAATO) appears feasible and safe at 6 months for stroke prevention in a high-risk AF patient with warfarin intolerance.
This report is of a 62-year-old woman presenting with a 3-year history of chronic atrial fibrillation (AF) and unable to tolerate chronic warfarin therapy due to bleeding episodes and unstable INR values. Additional high risk factors for stroke are a history of congestive heart failure and previous embolic stroke. Percutaneous left atrial appendage transcatheter occlusion (PLAATO ) was performed to seal the LAA. A transesophageal echocardiography (TEE) at the 1- and 6-month follow-up showed no device migration and no new thrombus related to the implant. The patient has been doing well on postprocedure aspirin with no embolic events.
No takes yet. Share an insight, caveat, or question.
Nakai et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: